info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Information, by types (DPaT, DTwP, Tdap) by applications (diphtheria, pertussis, tetanus,others) - Forecast to 2032


ID: MRFR/Pharma/0849-HCR | 115 Pages | Author: Kinjoll Dey| November 2024

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Overview


DPT vaccine Market Size was valued at USD 5.61 Billion in 2023. The Global DPT vaccine industry is projected to grow from USD 6.04 Billion in 2024 to USD 11.02 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.20% during the forecast period (2024 - 2032). DTP is the short form of diphtheria, tetanus, and pertussis. The immunization drug refers to certain vaccines used for the vaccination process. An increase in demand for the usage of tetravalent and pentavalent vaccines has played a great role in the shift. The rise in combination demand has increased to a greater extent and has been led by GAVI whereas funding for other DTP vaccines. The market comprises the revenue and the sale generated by the key players manufacturing certain vaccines which improves the sale of the product. DTP vaccination is one of the safest and most effective methods for creating a pertussis-free environment. In 2015, WHO made possible 86% vaccinations for infants suffering from DTP.


DPT vaccine Market Overview1


GSK has launched its new COiMMUNITY Initiative to improve adult vaccine uptake as healthcare professionals and public health leaders continue expressing concerns about adult vaccination rates post-pandemic. As part of the initiative, GSK has partnered with IQVIA to develop a new platform for tracking adult vaccination rates: Vaccine Track. Many preventative care protocols were put on hold in order to follow social distancing guidelines and minimize infectious disease transmission during the COVID-19 pandemic. Immunization rates have yet to rebound from the brink of the pandemic even as quarantines lifted and COVID-19 vaccines reinstated a new sense of normalcy. In addition, there is an increase in vaccine-preventable diseases such as polio and mpox, among others, that has been noted by the American Medical Association (AMA). Similarly, it is predicted that other old eradicated diseases like measles, mumps, and rubella can be prevented with MMR vaccination.


Sanofi Pasteur India announced on Wednesday that it had introduced booster vaccines for preschoolers against four main illnesses – diphtheria, pertussis-diphtheria-tetanus-polio (DTaP-IPV) named ‘Tetraxim’ vaccine by the company reduces pain due to reduced number of injections made in one place making it easier for parents and children.


Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company with a focus on developing novel vaccines for unmet medical needs in infectious diseases globally, and Serum Institute of India (SIIPL), the world’s largest manufacturer of vaccines by volume, today announced joint dosing of the first participant in Phase 1 clinical trial evaluating Tdap booster vaccine candidate adjuvanted with CpG 1018. Dynavax and SIIPL are collaborating on an adjuvanted Tdap vaccine development programme to overcome limitations associated with presently available acellular pertussis vaccines.


COVID 19 Analysis


The outburst of the pandemic has become a serious issue where the economic condition of the country has deteriorated. Moreover, this pandemic event disrupted the export-import business over the same period. This deteriorated the production unit of the market posing a shutdown in various other manufacturing units. It even brought a direct impact on the healthcare units, some of the chemical industries, and in ICT sectors. The pandemic led to the restriction in containment measures which included social distance measures and remote working. It led to the closing up of commercial activities which brought a great challenging factor for the environment. The outburst of the pandemic has helped in posing investment chances by pharma companies for some of their research activities.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Trends


Drivers


The increase in expansion of the DTP market is due to the rise in the death rate of children due to the very uncommon pertussis disease. The rise in awareness for the use of DTP vaccines is increasing the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market growth. To provide a holistic improvement some of the factors including demographics, microeconomic factors, and certain business cycles have helped raise the production of the market. A rise in the number of cases during the late spring period and early spring period helps in pushing up the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market size. The DTP market consists of the sale of the vaccine in the market which involves the treatment for diphtheria, tetanus, and pertussis-related disorders.


Opportunities


Adopting the various innovative ways for promoting growth brings more opportunities for rising Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market size. The presence of certain prime manufacturers raises the production value of the DTP vaccine thus promoting the growth rate. A rise in initiatives taken by the government and non-governmental organizations along with the growth in awareness about the vaccine has helped in spurring up the market size. The presence of upcoming key players has brought certain opportunities for the rising market players. For the further spread of infection, it has been made mandatory to minimize the number of people. The positive impact of vaccination drives helps the key players in occupying the large market share.


Challenges


The growth rate can be affected by the heavy competition of the key players along with the price wars so carried by the key players. Some of the adverse events if experienced by the nation becomes a challenging factor for improvement of market size. Some of the vaccinated injuries if experienced hampers up the market size and market growth.


Restraints- increase in costs of vaccine development along with incomplete access to vaccines hampers up the market development. Insufficient vaccinated or unvaccinated people are at a high stage of risk.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Segment Insights


By segmentation, it has been found that the market is divided into product, age group, end-users, and region.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Products Insights


Based on the product, the bifurcation is done as per the DTaP vaccine( Diphtheria Tetanus acellular Pertussis Vaccine) and Tdap( Tetanus Diphtheria acellular Pertussis Vaccine).


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Age Group Insights


Based on age group, the market is divided into adult and pediatric.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine End-Users Insights


The end-users segment is divided into clinics, medical centers, and some of the vaccination units.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Regional Insights


Regionally, the market has been classified into the North American region, some of the European region, Asia-Pacific, and some of the LAMEA region. It has been found DTaP has played a major Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market share during the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market forecast periodThe segment occupies a huge growth due to the rise in usage of and adoption of pertussis vaccines. The DTaP vaccine segment is classified into Boostrix, Daptacel, Citrix, infantry, Pentacle, Quaracel, Pediarix along with Adracel. The whole of the vaccine segment is classified into cellular and acellular vaccines. It was marked that a cellular vaccine had fewer side effects as compared to a cellular vaccine. Concerning age groups, the market has been classified into adult and pediatric groups.


Growth in technology has brought a revolutionary change and has helped in raising of new and innovative technologies while manufacturing the vaccine. Technology has also bought advancement and growth in therapeutic applications.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Regional Analysis


Regionally and globally, the North American region is found to occupy the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market share and occupies a high market value during the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market forecast period. This is because of the numerous increase in the death toll of children throughout the country. Europe is marked to be the second-largest market covering the second-largest Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market share. Moreover, the Asia Pacific region has been marked to occupy a major portion and is marked to be the largest DTP market. This is because they adopted new technology along with the rise in demand for DTP vaccines. The Increase in the adoption of new supplement vaccines has risen the prime factor for promotion.


Recent Developments


Merck in May 2020, in partnership with Thermos, developed innovative vaccines and immune-modulation therapies for certain infections. Thermal, the very renounceable company involved itself in discovering, developing, and production of DTP vaccines. Merck follows a versatile technology that invents the vaccine platform whereas the company becomes the fully owned subsidiary company. Thailand covers major vaccine coverage, before Japan and the Chinese region. Some of the Brazilian, South African, and Mexican regions pose a great opportunity which attributes to the growth and development of the companies present there. A rise in healthcare expenses along with the presence of private medical centers' insurance vaccination coverage pushes up great chances for promotion.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Competitive Landscape


Some of the key players operating in the market are



  • Merck and Co of the United States region,

  • Chiron Pharmaceutical Pvt Ltd of India,

  • Sanofi of France,

  • Wyeth of the United States,

  • GSK of the United States,

  • Serum Institute of India Pvt Ltd,

  • Panacea Biotec Ltd,

  • Johnson and Johnson,

  • Bionet-Asia, Meiji Holdings Co. Ltd,

  • Lanzhou Institute of biological products of the Chinese region,

  • and many more.


These key players analyze their competencies and from the herd, it draws a competitive landscape about the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market. They also carry out certain competitive development procedures like joint ventures, product launching, merging, and acquisition by carrying out certain research and developmental activities. The key players are majorly focussing on building a strong relationship with other market players along with dealers and manufacturers. These players are collaborating with other players to expand their global reach and their company portfolio.


Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market Report Overview


From the market research report, it has been noted that the report provides extensive research and gives a perfect analysis of the qualitative and quantitative research activities going on in the market. The report highlights the key players playing in the market for promoting the market growth. It also provides a vivid picture of the whole of the market scenario. It signifies the growing market structure, volume, and value so occupied by it. It signifies the technological advancement done for promoting and raising the growth of the DTP vaccine. It symbolizes the microeconomics l and macroeconomic factors along with the governing factors helping in improving the Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market size.


It gives detailed information and analysis about the strategies of the market players. It gives a widened study about the market segmentation being done which helps in raising the expansion of Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market size. It provides insights about the driving factors and other market dynamic factors helping in promoting the market growth. It gives a good analysis of the factors such as supply chain analysis, porter five analysis, and value chain analysis. It gives insights into revenue generation and the revenue scale of the industry. It gives regional and country-level analysis from the future perspective. It gives a market overview analysis and the partnership so made for improving the launching and promoting growth.

Report Attribute/Metric Details
  Market Size   2032 : USD 11.02 Billion
  CAGR   8.20% : (2024-2032)
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Types, By Applications
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India) and many others
  Key Market Opportunities   Increasing deaths in children due to pertussis
  Key Market Drivers   Increasing the growth of DPT vaccine market


Frequently Asked Questions (FAQ) :

Global DPT Vaccine Market is expected to expand at 8.20% CAGR from 2024 to 2032.

Global DPT Vaccine Market is driven by the rising mortality rate in children due to pertussis.

Global DPT Vaccine Market growth can be impeded by heavy completion and price wars between market players.

North America is predicted to dominate the Global DPT Vaccine Market.

GSK, Sanofi, Chiron Pharmaceutical Pvt Ltd, Lanzhou Institute of Biological Products, Merck & Co., Inc, and Wyeth are the key players of the Global DPT Vaccine Market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.